ArticleMedical cannabis and cannabinoids
Oral Cannabidiol in the Treatment of Myofascial Pain Disorder of the Temporomandibular Region: A Placebo-Controlled Randomized Clinical Trial.
Article in Medical cannabis and cannabinoids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The efficacy of oral cannabidiol (CBD) for the management of myofascial pain disorder (MPD) of the temporomandibular region remains understudied. Therefore, the purpose of this study was to determine whether cannabinoids provide pain relief and improve jaw function in patients with MPD of the temporomandibular region. Methods: This is a single-center, prospective, double-blind, randomized, and placebo-controlled clinical trial. Subjects with pain (≥30 on Visual Analog Scale [VAS]) were screened for MPD as defined by the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). The primary predictor variable was MPD treatment with random assignment to CBD or placebo (hemp seed oil). The primary outcome variable was jaw pain, measured by VAS, at 1 month (T1). The secondary outcome variable was pain at 2 months (T2) and 3 months (T3), and jaw function (evaluated using the Jaw Functional Limitation Scale) measured at all timepoints. An exploratory variable is the occurrence of adverse effects from CBD oil versus placebo. Statistical tests included the chi-squared test, Friedman rank-sum test, and Wilcoxon rank-sum test. Results: A total of 54 subjects with a median age of 36 (interquartile range: 30, 51) and 32 (28, 39) years in the CBD oil and placebo groups, respectively ( Conclusion: Both CBD and hemp seed oil did appear to improve jaw function over time, but neither treatment improved pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.